

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

### HB से लेकर MRI तक एक ही छत के नीचे

Name : Mrs. SHREYA W/o **UHID:** 112918 **PID:** 25095

Age/Gender: 30 Year/Female Sample Date : 23-Mar-2024 02:36 PM

Ref. By Dr. : **MEDIWHEEL** Report Date : 23-Mar-2024

**Address** : HISAR Sample Type: Inside \*25095\*

Test Name	Value	Unit	Reference Range
	HEAMATOLOGY		
CBC (Complete Blood Count)			
Haemoglobin (Hb)	11.7	g/dl	12.0 - 15.0 g/dl
Total RBC Count	4.48	m/cumm	4.20 - 5.40
Haematocrit	34.5	%	35.0 - 50.0 %
Mean Cell Volume	77.0	fL	80.0 - 100 fL
Mean Cell Haemoglobin	26.1	pg	27.0 - 34.0 pg
Mean Cell Haemoglobin Conc	33.9	%	32.0 - 36.0
Red Cell Distribution Width (RDW) - SD	43.2	fL	35.0 - 56.0 fL
Red Cell Distribution Width (RDW) - CV	13.8	%	11.0 - 16.0 %
Total Leucocyte Count	5030	cells/cum	4000 - 11000
		m	
Differential Leucocyte Count			
Neutrophils	70	%	32 - 72 %
Lymphocytes	20	%	20 - 50 %
Monocytes	5	%	2 - 11 %
Eosinophils	3	%	1 - 3 %
Basophils	2	%	0 - 2 %
Platelet Count	1,58,000	cells/cunm	150,000 - 450,000
		m	
Platelet Distribution Width	16.6	fL	15.0 - 18.0 fL
Mean Platelet Volume	11.7	fL	7.0 - 13.0 fL
Sample Type: Whole Blood			

- 1. Spurious elevation of platelet count may be seen in patients with extensive burns, extreme microcytosis ,microangiopathic hemolytic anemia, red cell fragmentation ,micro-organisms like bacteria, fungi or yeast, hyperlipidemia, fragments of white blood cell (WBC) cytoplasm in patients with acute leukemia, hairy cell leukemia, lymphomas and in presence of cryoglobulins.
- 2.Spuriously low platelet counts may be seen in cases of platelet clumping (EDTA induced, platelet cold agglutinins, multiple myeloma), platelet satellitism and in giant platelet syndromes.
- 3.Delay in processing due to sample transport may cause a mild time dependent fall in platelet count. It is advisable to repeat the test using a citrate / heparin collection tube to avoid this pitfall.
- 4. Automated platelet counting is subject to 10-15% variation in the result on the same as well as different analysers due to various preanalytic variables like the sampling site ,skill in sample collection, anticoagulant used ,sample mixing and sample transport etc.

#### **ABO Blood Grouping**

A" POSITIVE **Blood Group** 

Haemaqqlutination reaction
A Rh Positive,B Rh Positive,AB Rh Positive,O Rh Positive,A Rh Negative,B Rh Negative,AB Rh Negative,O Rh Negative

Sample Type : Whole Blood

HBA1C

5.3 4.27 - 6.00 % HBA1C

turbidimetric immunoassay

Dr. Amit Verma MBBS, MD Consultant Physician





Name : Mrs. SHREYA W/o **UHID:** 112918

**PID:** 25095 02:36 PM

Age/Gender: 30 Year/Female Sample Date : 23-Mar-2024 Report Date : 23-Mar-2024

Ref. By Dr. : **MEDIWHEEL** 

**Address** : HISAR Sample Type: Inside \*25095\*

Value Unit **Test Name** Reference Range HBA1C 90.00 - 120.00 mg/dl Average Blood Glucose 105.41 mg/dl Average 2.2 turbidimetric immunoassay Type: Whole Blood

Remarks:

GLYCOSYLATED HEMOGLOBIN (HbA1c)

Reference Range: Please correlate with clinical conditions.

Bellow 6.0 % Normal value 6.0 %-7.0 % Good control 7.0 %-8.0 % Fair control

8.0 %-10 % Unsatisfactory control

Above10 % Poor control

Technology: Immunoassay and chemistry technology to measure A1C and total HB (A1C now Bayer)

AVERAGE BLOOD GLUCOSE (ABG) CALCULATED

Reference Range: Please correlate with clinical conditions.

90-120 mg/dl Excellent control 121-150 mg/d Good control 151-180 mg/dl Average control 181-210 mg/dl Action suggested

> 211 mg/dl Panic values

NOTE: Average blood glucose value is calculated from HbA1C value and it indicates average blood sugar level over

past three months.

Technology: Derived from Hb A1C Values

Sample Type: Sodium heparin:

**ESR** 

**ESR** 20 0 - 20 mmHr mmHr

Sample Type : Whole Blood





Name : Mrs. SHREYA W/o UHID : 112918 PID : 25095

Age/Gender: 30 Year/Female Sample Date: 23-Mar-2024 02:36 PM

Ref. By Dr. : MEDIWHEEL Report Date : 23-Mar-2024

Address : HISAR Sample Type : Inside \*25005\*

Test Name Value Unit Reference Range

#### CLINICAL COMMENTS:

Erythrocyte sedimentation rate (ESR or sed rate) is a relatively simple, inexpensive, non-specifictest that indirectly measures the degree of

inflammation present in the body. Inflammation is part of the body's immune response. It can be acute, developing rapidly after trauma.

injury or infection, for example, or can occur over an extended time (chronic) with conditions such as autoimmune diseases or cancer.

Moderately elevated ESR occurs with inflammation but also with anemia, infection, pregnancy, and with aging. A very high ESR usually has

an obvious cause, such as a severe infection, marked by an increase in globulins, systemic vasculitis, polymyalgia rheumatica or temporal

arteritis. People with multiple myeloma or Waldenstrom's macroglobulinemia (tumors that make large amounts of immunoglobulins) typically

have very high ESRs even if they don't have inflammation.

Factors increasing ESR:

Advanced age

Anemia

Pregnancy

High fibrinogen

Macrocytosis

Kidney problems

Thyroid disease

Some cancers, such as multiple myeloma

Infection

Factors decreasing ESR

Microcytosis

Low fibrinogen

Polycythemia

Marked leukocytosis

#### **CLINICAL-CHEMISTRY**

#### **URIC ACID**

Uric acid 5.23 mg/dL 2.5 - 6.0

Uricase - POD

Sample Type: SERUM

URIC ACID: Increases in case of renal failure, disseminated neoplasms, pregnancy toxaemia, psoriasis, liver disease, sarcoidosis etc. Decrease is reported in Wilson's disease, Fanconi's syndrome,

xanthinuria.

Glucose.Fasting

Glucose, Fasting 90.8 mg/dl 70 - 100 mg/dl

Hexokinase / GOD - POD

Sample Type: SERUM

**Total Protein** 

Total Protein 7.86 gm/dl 6.0 - 8.3

BIURET

Dr. (Maj.)Guruprasad MBBS, DMRD, DNB Consultant Radiologist Dr. Rambaksh Sharma MBBS, MD Consultant Radiologist Dr. RAJESH REDDU MBBS, DMRD Consultant Radiologist Dr. Amit Verma MBBS, MD Consultant Physician



Name : Mrs. SHREYA W/o UHID : 112918 PID : 25095

Age/Gender: 30 Year/Female Sample Date: 23-Mar-2024 02:36 PM

Ref. By Dr. : MEDIWHEEL Report Date : 23-Mar-2024

Address : HISAR Sample Type : Inside \*25095\*

Test Name	Value	Unit	Reference Range	
Total Protein				
Albumin	4.23	g/dl	2.9 - 4.5	
BCG Globulin	3.63	gm/dl	2.0 - 3.5	
Albumin-Globulin Ratio	0.6	Ü	1.2 - 2.5	
Sample Type : SERUM				
LIVER FUNCTION TEST (LFT) (S)				
Total Bilirubin-Serum	0.90	mg/dl	0.20 - 1.00 mg/dl	
Bilirubin Direct Serum	0.40	mg/dl	0.10 - 0.50 mg/dl	
Bilirubin Indirect-Serum	0.50	mg/dl	0.20 - 0.70 mg/dl	
SGOT	23.98	IU/L	10 - 40 IU/L	
IFCC with Pyridoxal Phosphate SGPT	25.68	IU/L	07 - 56 IU/L	
IFCC with Pvridoxal Phosphate Alkaline Phosphatase	129.6	U/L	44 - 147 U/L	
IFCC PNPP Buffer Total Protein	7.98	gm/dl	6.0 - 8.3	
BIURET Albumin	4.35	g/dl	3.5 - 5.5 g/dl	
BCG Globulin	3.63	gm/dl	2.0 - 3.5 gm/dl	
AG RATIO	2.4		1.2 - 2.5	
Sample Type : SERUM				

## CLINICAL COMMENT:

Liver function tests can be suggested in case of hepatitis, liver cirrhosis and monitor possible side effects of medications. A variety of diseases and infections can cause acute or chronic damage to the liver, causing inflammation (hepatitis), scarring (cirrhosis), bile duct obstructions, liver tumors, and liver dysfunction. Alcohol, drugs, some herbal supplements, and toxins can also inure the liver. A significant amount of liver damage may occur before symptoms such as jaundice, dark urine, light-colored stools, itching (pruritus), nausea, fatigue, diarrhea, and unexplained weight loss or gain appear. Early detection of liver injury is essential in order to minimize damage and preserve liver function.

Alanine aminotransferase (ALT) A very high level of ALT is frequently seen with acute hepatitis. Moderate increases may be seen with chronic hepatitis. People with blocked bile ducts, cirrhosis, and liver cancer may have ALT concentrations that are only moderately elevated or close to normal. Aspartate aminotransferase (AST) A very high level of AST is frequently seen with acute hepatitis. AST may be normal to moderately increased with chronic hepatitis. In people with blocked bile ducts, cirrhosis, and liver cancer, AST concentrations may be moderately increased or close to normal. When liver damage is due to alcohol, AST often increases much more than ALT (this is a pattern seen with few other liver diseases). AST is also increased after heart attacks and with muscle injury. AST is a less sensitive and less specific marker of liver injury than ALT. AST is more elevated than ALT in alcohol-induced liver injury. AST could elevated more than ALT like: (i)

**Lipid Profile** 

 Cholesterol
 128.7
 mg/dl
 <200.0 mg/dl</td>

 CHOD - PAP
 Triglycerides
 68.2
 mg/dl
 < 150 mg/dl</td>

 GPO - PAP
 GPO - PAP
 - PAP<

Dr. (Maj.)Guruprasad MBBS, DMRD, DNB Dr. Rambaksh Sharma MBBS, MD Consultant Radiologist Dr. RAJESH REDDU MBBS, DMRD Consultant Radiologist Dr. Amit Verma MBBS, MD Consultant Physician



Name : Mrs. SHREYA W/o UHID : 112918 PID : 25095

Age/Gender: 30 Year/Female Sample Date: 23-Mar-2024 02:36 PM

Ref. By Dr. : MEDIWHEEL Report Date : 23-Mar-2024

Address : HISAR Sample Type : Inside \*25005\*

Test Name	Value	Unit	Reference Range
Lipid Profile			
HDL Cholesterol	43.56	mg/dl	Adult females >55 mg/dl
Homogeneous Enzymatic Colorimetric test LDL Cholesterol	71.5	mg/dl	<100 mg/dl
VLDL Cholesterol	13.64	mg/dl	<30.0 mg/dl
CHO/HDL Ratio	2.95	mg/dl	Low risk 3.3-4.4
Non HDL Cholesterol Calculated	85.14	mg/dl	<130 mg/dl

Sample Type : SERUM

PHYSICAL EXAMINATION

Interpretation Note

- 1. Measurements in the same patient can show physiological analytical variations. 3 serial samples 1 wk apart are recommended for Total Cholesterol, Triglycerides, HDL LDL Cholesterol.
- 2. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogenic lipoproteins such as LDL , VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDL.
- 3. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL & Non HDL goals have been achieved.
- 4. Additional testing for Apolipoprotein B, hsCRP, Lp(a ) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement.

#### **CLINICAL PATHOLOGY**

PHI SICAL EXAMINATION	•		
Colour	PALE-YELLOW		
Pale-yellow,Yellowish,Colorless,YELLOW			
Quantity	40	ml	
рН	6.0		
Mucus	ABSENT		
Absent, Present			
Appearance	TURBID		
Slightly turbid,Turbid,Clear			
Chemical Examination (Strip)			
Specific Gravity	1.025		
Albumin	NEGATIVE		
Absent,Present(+),Present(2+),Present(3+)			
Sugar	NEGATIVE		
Absent,Present(+),Present(2+),Present(3+)			
Bilirubin	NEGATIVE		
Absent, Present			
Microscopic Examination (Microscopy)	•		
Pus Cells	10-12	/HPF	
Epithelial Cells	6-8	/HPF	
RBC	NIL	/HPF	
Casts	ABSENT		
Crystals	ABSENT		
Bacteria	ABSENT		

Dr. (Maj.)Guruprasad MBBS, DMRD, DNB Consultant Radiologist Dr. Rambaksh Sharma MBBS, MD Consultant Radiologist Dr. RAJESH REDDU MBBS, DMRD Consultant Radiologist Dr. Amit Verma MBBS, MD Consultant Physician





Name : Mrs. SHREYA W/o UHID : 112918 PID : 25095

Age/Gender: 30 Year/Female Sample Date: 23-Mar-2024 02:36 PM

Ref. By Dr. : MEDIWHEEL Report Date : 23-Mar-2024

Address : HISAR Sample Type : Inside \*25095\*

Test Name Value Unit Reference Range

Others

Sample Type: Urine

#### **ENDOCRINE**

#### Thyroid Hormones (T3 .T4 & TSH)

T3	0.98	ng/ml	0.60 - 1.81 ng/ml
T4	8.26	ng/dl	5.01 - 12.45 ng/dl
TSH Ultrasensitive	2.48	ulU/ml	0.34 - 5.50 uIU/mI

Sample Type : SERUM

#### Remarks:

Note1.TSH levels are subject to circadian variation, reaching peak levels between 2-4.a.m and at a minium between 6-10 pm. The variation is of the 50 %, hence time of the day has influence on the measured serum TSH concentrations.

- 2. Recommended test for T3 and T4 unbound or free level as it is metabollically active.
- 3. Physiological rise in Total T3 and T4 level is seen in pregnancy and in patients on steroid therapy.

#### Clinical Use-

- \* Primary Hypothyroidism
- \* Hperthyroidism
- \* Hypothalamic- Pituitary hypothyroidism
- \* Inappropriate-TSH secretion
- \* Nonthyroidal illness
- \* Autoimmune thyroid disease
- \* Pregnency associated thyroid disorders
- \* Thyroid dysfunction in infancy and early childhood

--End of Report--



Dr. Rambaksh Sharma MBBS, MD Consultant Radiologist Dr. RAJESH REDDU MBBS, DMRD Consultant Radiologist Dr. Amit Verma MBBS, MD Consultant Physician



# Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

PATIENT NAME: SHREYA

REF BY: TPA

AGE/SEX: 30 YRS/F DATE: MARCH 23, 2024

## USG WHOLE ABDOMEN

Liver: normal in size (measures 11.6 cm). Parenchymal echotexture is normal and no focal area of altered echogenicity is seen. IHBR not dilated. CBD is normal in diameter.

GB: is normal, Wall thickness is normal.

Pancreas: head and body shows normal size and parenchymal attenuation.

Spleen: normal in size and normal echotexture.

Right Kidney: is normal in position, size and morphology. No evidence of any calculus detected. Pelvi calyceal system is normal. CMD is maintained.

Left Kidney: is normal in position, size and morphology. No evidence of any calculus detected. Pelvi calyceal system is normal. CMD is maintained.

Urinary Bladder: appears normal.

Uterus: is normal in size. E.T- 11.9 mm. No focal lesion seen.

B/L ovaries are normal in size. No adnexal mass lesion seen.

No obvious abnormal bowel dilatation or wall thickening is seen in present scan.

**IMPRESSION**: - No significant abnormality seen sonologically

Clinical correlation and further evaluation is suggested.

Dr. Ram Baksh Sharma

Radiologist

Dr. Rambaksh Sharma Consultant Radiologist

No free fluid seen.

Dr. Anshul Jain Consultant Radiologist

Dr. Rajesh Reddu MBBS, DMRD Consultant Radiologist **Dr. Amit Verma** Echocardiography Specialist Dr. Sonam Aneja Consultant Pathologist



# Lotus Diagnostic & Imaging Centre

A Unit of Lotus Diagnostic & Imaging Solution Pvt. Ltd.

HB से लेकर MRI तक एक ही छत के नीचे

PATIENT NAME: SHREYA

REF BY: TPA

AGE/SEX: 30 YRS/F DATE: MARCH 23, 2024

## USG WHOLE ABDOMEN

Liver: normal in size (measures 11.6 cm). Parenchymal echotexture is normal and no focal area of altered echogenicity is seen. IHBR not dilated. CBD is normal in diameter.

GB: is normal, Wall thickness is normal.

Pancreas: head and body shows normal size and parenchymal attenuation.

Spleen: normal in size and normal echotexture.

Right Kidney: is normal in position, size and morphology. No evidence of any calculus detected. Pelvi calyceal system is normal. CMD is maintained.

Left Kidney: is normal in position, size and morphology. No evidence of any calculus detected. Pelvi calyceal system is normal. CMD is maintained.

Urinary Bladder: appears normal.

Uterus: is normal in size. E.T- 11.9 mm. No focal lesion seen.

B/L ovaries are normal in size. No adnexal mass lesion seen.

No obvious abnormal bowel dilatation or wall thickening is seen in present scan.

**IMPRESSION**: - No significant abnormality seen sonologically

Clinical correlation and further evaluation is suggested.

Dr. Ram Baksh Sharma

Radiologist

Dr. Rambaksh Sharma Consultant Radiologist

No free fluid seen.

Dr. Anshul Jain Consultant Radiologist

Dr. Rajesh Reddu MBBS, DMRD Consultant Radiologist **Dr. Amit Verma** Echocardiography Specialist Dr. Sonam Aneja Consultant Pathologist